Compare UiPath Inc (PATH) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
UiPath Inc vs Zoetis Inc — how do they compare? UiPath Inc trades at $13.28 (market cap $6.81B), while Zoetis Inc trades at $73.02 (market cap $29.57B). The key difference: Zoetis Inc is far larger — about 4.3× UiPath Inc's market cap, and Zoetis Inc pays a 2.96% dividend while UiPath Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold UiPath Inc for 139 Days and Zoetis Inc for 70 Days on average.
| PATH | ZTS | |
|---|---|---|
Market Cap | $6.81B | $29.57B |
Volume | 22,766,109 | 4,128,093 |
Sector | Technology | Health |
52-Week High | $19.29 | $147.53 |
52-Week Low | $9.38 | $69.09 |
Typical Hold Time | 139 Days | 70 Days |
Enterprise Value | $5.61B | $37.13B |
Dividend Yield | — | 2.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
UiPath (PATH) trades at $13.25, up 1.15% with mixed technical signals showing bearish momentum but neutral oscillators. The company demonstrates improving fundamentals with revenue growing from $1.43B in 2025 to projected $1.7B in 2026, while transitioning from net losses to profitability. Recent partnerships with Snowflake and BDO highlight strategic positioning in AI automation, though the stock faces near-term headwinds from valuation concerns and competitive pressures.
PATH presents a turnaround story with strong revenue growth and path to profitability, but faces execution risks amid competitive automation landscape. The consensus price target of $15.13 suggests 14% upside potential, though technical weakness and mixed analyst sentiment warrant caution. Key catalysts include AI platform adoption and enterprise expansion, while risks involve growth sustainability and margin pressures.
Zoetis (ZTS) trades at $73.08, up 2.47% on the day, but remains in a bearish technical trend with support near $70. Fundamentally, the company reported strong 2025 results with $9.47B revenue, $2.67B net income, and robust margins, though recent quarters show mixed earnings performance. Analyst consensus is a Buy with a $87.33 price target, but sentiment is cautious due to U.S. pet care weakness and competitive pressures.
The stock offers value with a P/E of 11.67 and a 3% dividend yield, but near-term headwinds include declining U.S. companion animal sales and margin compression. Long-term growth prospects remain intact given industry leadership and international resilience, making it a contrarian opportunity for patient investors despite technical and competitive risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
